Coronavirus / COVID

A team of investigators lay out 3 scenarios for the global pandemic duration—based on previous pandemic learning and public health adherence.

Cornelius J. Clancy, MD, discusses navigating partial trial information and the need for coherent national coordination on the COVID-19 response.

Midway through the pandemic outbreak, investigators attempts to highlight some of the strongest candidates to fight the disease.

The test reports ≥99.8% specificity and 100% sensitivity at 14 days post-PCR confirmation, and could potentially better inform patient immunity and disease pathology.

Commentary outlines “best practices” for studies looking into possible treatments, vaccine.

Contagion Editor in Chief Jason Gallagher, PharmD, discusses the new authorization for the controversial antiviral therapy.

The decision comes shortly after conflicting human trial results assessing the intravenous antiviral drug.

A brief summary of our daily COVID-19 coverage.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

In a study of patients in China, investigators found most men were more likely than women to have severe cases of COVID-19, and more likely to die from the disease.

Children who were confined to their homes due to the COVID-19 outbreak in Hubei province, China, reported higher rates of depressive symptoms and anxiety.

The FDA has added a ventilator developed by NASA to the list of authorized ventilators.

Studies should be done in humans to gain insight, before making recommendations solely on lab results, the study authors said.

A round up of the top infectious disease news from April.

Half of surveyed hospitals have no ventilator triage policies, and existing policies differ substantially and often lack guidance on implementation.

"Operation Warp Speed" seeks to develop and disburse 100 million doses of a COVID-19 vaccine to the public by year’s end.

A review of our latest COVID-19 coverage.

If half of Americans eventually get infected with the novel coronavirus, the US healthcare system could face costs of more than $400 billion, a new study finds.

Treatment with remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.

Michael K. Gusmano, PhD, discusses the importance of maintaining ethical standards in research evaluating potential therapeutics and vaccines for COVID-19.

A New York City nurse reflects on "peak-week" in a COVID unit.

The SIMPLE trial appears to have demonstrated that patients receiving the 5-day dose duration achieved similar improvement in clinical status compared to patients who received the 10-day dosing duration.

US and China research shows the coronavirus is not present in semen samples, unlike Ebola and the Zika virus.

Investigators aim to assess a vaccine derived from weakened adenovirus in 1100 patients over 2-6 months.

About 10% of older Britons were hospitalized for respiratory disease in a new sudy. But patients who lived alone faced triple the risk.

A daily round up of our COVID-19 coverage.

Hollis O’Neal, MD, the national primary investigator for the Cytovale early sepsis detection system, discusses sepsis and COVID-19 and provides an overview of his pilot study.

Over half of residents with positive test results were asymptomatic at the time of testing, during a recent survey.

A trio of clinicians pen perspective on the federal and state efforts being made to reduce rapid and severe virus spread in at-risk facilities.

A pair of experts cite fair innings in their debate, wondering if age should play a role in deciding who qualifies for life-saving coronavirus treatments.